75 Search Results


Search Again

Gary Goodman , MD, MS

Email: gary.goodman@swedish.org

Phone: (206) 667-5722

Dr. Goodman is specialized in internal medicine. His clinical interests are: General Medical Oncology, Lung Cancer, Melanoma, Ovarian Cancer, Renal Cell Cancer and Sarcoma.

View Bio

Bernardo Goulart , MD, MS

Email: bgoulart@fredhutch.org

Phone: (206) 667-2778

Dr. Goulart treats patients for lung cancer and head and neck cancers. His research interests include: Head and neck and lung cancer outcomes research; economical evaluations of head and neck and lung cancer therapies; comparative effectiveness research in cancer and cost-effectiveness analyzes of cancer interventions.

View Bio

Barry Gumbiner , PhD

Email: gumbiner@uw.edu

Phone: 206-884-5116

Dr. Gumbiner and his team study how cadherin cell adhesion molecules and associated catenin proteins control tumor development and progression. Cadherins and catenins play important roles in the morphogenesis, maintenance, and regeneration of tissues, and alterations in their functions are important in cancer. One major effort of the laboratory is to understand how cadherins signal into the cell to control growth and differentiation through regulation of both the Wnt-beta-catenin pathway and the Hippo signaling pathway; the latter inhibits cell proliferation and participates in organ size control. Cadherins mediate contact inhibition of growth by stimulating the Hippo pathway, while growth factors, such as EGF, inhibit the Hippo pathway. They are investigating how these modes of regulation of the Hippo pathway affect the development of different types of tumors. Another major effort of the laboratory is to understand how cadherin adhesive function at the cell surface is regulated to control tissue architecture and tumor cell invasion. Loss of E-cadherin expression associated with the epithelial-mesenchymal transition (EMT) is known to promote tumorigenesis and metastasis. However, many tumors and metastases retain E-cadherin expression, and they have found that instead it can be inactivated at the cell surface to cause the loss in function. They have generated a novel class of monoclonal antibodies that activate E-cadherin at the cell surface to restore its adhesive function, and are evaluating whether they reduce tumor invasion and metastasis in animal models. He and his team are also studying how catenins and cancer-associated mutations in E-cadherin affect its ability to switch to the active state and regulate tumor development. The mechanisms by which cadherins and catenins affect tumor growth are varied and complex and offer potential approaches for intervention.

View Bio

Stephen Hawes , PhD

Email: hawes@u.washington.edu

Phone: (206) 616-9744

Dr. Hawes's primary interests are in human papillomavirus (HPV) and human immunodeficiency virus (HIV). His current research is conducted in Seattle and Senegal, West Africa and concerns the role of HIV, HPV and other sexually transmitted infections in the natural history of cervical neoplasia and cancer, as well as the study of biomarkers for various cancers including cancer of the cervix, anus, lung, breast, and skin. He is also interested in Alzheimer's disease.

View Bio

Mark Headley , PhD

Email: mheadley@fredhutch.org

Phone: (206) 667-3619

Dr. Headley is working to understand the cellular and molecular dynamics that underlie tumor metastasis (the spread of cancer cells from a primary tumor to distant organs). The main focus of his lab is to understand how tumor-immune cell interactions variably promote or defend against metastasis. For most cancer patients, metastasis is the leading cause of death. Of particular note, metastasis to the lung is one of the most common and most detrimental sites of tumor spread, and Dr. Headley is especially interested in understanding lung metastasis. He has developed a suite of cutting-edge tools to enable these studies. His lab uses advanced microscopy and surgical techniques to directly visualize tumor cells and immune cells in live lungs in real-time, interrogating the unique lung environment during tumor metastasis with unprecedented detail by pairing this unique microscopy approach with high-resolution single cell profiling. Dr. Headley has recently identified a unique process by which burgeoning metastatic cells shed large cytoplasmic particles from the earliest moments of metastasis. These particles, known as cytoplasts or microparticles, form a platform for engaging a particular class of immune cells called myeloid cells. Notably, during the first hours of metastasis, particular myeloid cells with protumoral properties (macrophages) versus anti-tumoral properties (dendritic cells and patrolling monocytes) encounter and ingest the tumor-derived particles. Dr. Headley seeks to understand how this particular facet of immune-tumor engagement defines anti-tumor immune responses and patient outcomes. His findings will be critical to designing new therapies that can debilitate prometastatic myeloid cell functions while enhancing anti-tumor functions, thereby saving more lives.

View Bio

Noah Hoffman , MD, PhD

Email: ngh2@uw.edu

Phone: (206) 598-7932

Dr. Hoffman's clinical interests and responsibilities include the development and application of software and processes for the collection, management, and display of data generated in the clinical laboratory. His research is focused on creating applications and algorithms to classify medically important microorganisms using biological sequence information.

View Bio

Leroy (Lee) Hood , MD, PhD

Email: lhood@systemsbiology.org

Phone: (206) 732-1200

The Hood group is integrating biology, technology and computation to create a predictive, personalized, preventive and participatory approach to medicine. His projects center on cancer biology of prostate, glioblastoma and lung cancers, systems approach to prion disease in glioblastoma mouse models, new strategies for obtaining blood biomarkers, and a systems approach to diagnosis and stratification of disease.

View Bio

A. McGarry Houghton , MD

Email: houghton@fredhutch.org

Phone: (206) 667-3175

Dr. Houghton is a pulmonologist and specializes in critical care, pulmonary complications of malignant disease, and lung cancer. He has conducted research on lung cancer, COPD/emphysema, acute lung injury, pulmonary infections, and pulmonary fibrosis. More recently, his group is investigating the role of innate immune cells within the tumor microenvironment, beginning with how they have been recruited, and followed by understanding of the mechanism by which a specific immune cell effector has impacted lung tumor growth.

View Bio

Billanna Hwang , MPH, DHSc

Email: bhwang@uw.edu

Dr. Hwang’s research focuses include development of immunotherapies in lung and VCA transplants, tolerance and acute/chronic rejection immunology (Tregs), pathophysiology of GVHD, NSCLC, and exosome biology (therapies, biomarker). Most recently, her group has expanded using cell and exosome based immunotherapies in Cystic Fibrosis and role of bioengineered materials to promote regeneration through exo-mechanisms.

View Bio

Christopher Kemp , PhD

Email: cjkemp@fredhutch.org

Phone: (206) 667-4252

Dr. Kemp is an expert on tumor suppressor genes and their roles in cancer progression and response to therapy. In addition to using mouse models to understand cancer biology, Dr. Kemp has pioneered the use of mouse models for identifying new biomarkers of cancer and for identifying new cancer drug targets using functional genomics. Dr. Kemp plays a leading role in several national research consortia including the NCI's Mouse Models of Human Cancer Consortia and the Cancer Target Discovery and Development Network. Dr. Kemp's research focuses on understanding how environmental exposure to carcinogens interacting with the genetic susceptibility of the host leads to cancer. He studies multistage carcinogenesis in the mouse in order to model the entire natural history of neoplastic development from the initiated cell to clonal evolution to a fully malignant tumor. His work focuses on the role of the p53 signaling pathway in various cancer models.

View Bio

Linda Ko , PhD, MPH

Email: lko@fhcrc.org

Phone: (206) 667-7182

Dr. Ko is the director of the Center for Health Communication Intervention (CHEALCI). She is a behavioral scientist with expertise in the development, testing, and evaluation of health communication strategies. Her work draws from the discipline of communication, marketing, social epidemiology, and social and behavioral sciences. Her research aims to understand community behavior within the socio-cultural context, develop interventions that will address those behaviors and translate knowledge through community-based participatory research.

View Bio

Paul Lampe , PhD

Email: plampe@fredhutch.org

Phone: (206) 667-4123

Dr. Lampe and his lab investigate the control of cell growth both at the cell biological/ mechanistic level and through cancer biomarker discovery. He studies the cell biology connecting gap junctions and intercellular communication (GJIC) with the control of cell growth, the cell cycle and, how the relationship is disrupted during carcinogenesis. To perform these studies he utilizes a variety of cell, molecular and biochemical techniques including GFP chimeras to monitor gap junctions in living cells.

View Bio

Simon Lo , MD; Ch.B; FACR

Email: simonslo@uw.edu

Dr. Lo is a nationally and internationally renowned clinician, scholar and expert in advanced stereotactic radiation therapy techniques in brain tumors and tumors outside the CNS. In addition to his extensive expertise in CNS tumors, Dr. Lo has also been on the leading edge of expanding image-guided stereotactic radiation techniques beyond the brain to multiple other tumor sites, and his work has set the standard in clinical applications and care of patients in this area. He has made major contributions to the advancement of these innovative treatment techniques, translating them and increasing their efficacy and therapeutic ratio.

View Bio

David MacPherson , PhD

Email: dmacpher@fredhutch.org

Phone: (206) 667-6464

Dr. MacPherson studies two tumor types, small cell lung carcinoma (SCLC) and retinoblastoma. He conducts genomic analyses of human tumors to identify gene mutations that may contribute to tumor initiation, progression and metastasis. His goal is to understand the mechanisms through which cancer-mutated genes drive tumorigenesis, small cell lung carcinoma (SCLC) and retinoblastoma.

View Bio

David Madtes , MD

Email: dmadtes@fredhutch.org

Phone: (206) 667-4589

Dr. Madtes is a pulmonary and critical care specialist whose clinical and research expertise are in lung cancer early detection and prevention using ultra-low-dose CT imaging, and the treatment of pulmonary complications from bone marrow transplant (BMT) and general oncology.

View Bio

Renato Martins , MD, MPH

Email: rgmart@uw.edu

Phone: (206) 288-2048

Dr. Martins is a medical oncologist who specializes in lung cancer, head and neck cancer, clinical trial design, and new drug development.

View Bio

Martin McIntosh , PhD

Email: mmcintos@fredhutch.org

Phone: (206) 667-4612

Dr. McIntosh focuses on identifying the role of transcriptional and translational changes in cancer that lead to the formation of tumor antigens (neoantigens) and an adaptive immune response, primarily in ovarian and lung cancer. Once found our goal is to exploit immune-based approaches to kill the malignant cells that harbor the immunogenic molecular alterations, or to prevent the cancer using tumor vaccines.

View Bio

David Myerson , MD

Email: dmyerson@fredhutch.org

Phone: (206) 606-2047

Dr. Myerson is a pathologist at the Seattle Cancer Care Alliance and a UW associate professor of pathology. His specialty is bone marrow transplant pathology and infectious disease pathology. He has a long-standing interest in the detection of virus infection in tissue biopsies by microscopy, including the pathology of cytomegalovirus (CMV) and human herpesvirus 6 (HHV6). He has extensive experience in diagnosing the complications of bone marrow transplantation, such as graft-versus-host disease, lung and liver dysfunction. He is one of 4 dedicated bone marrow transplant pathologists at the SCCA.

View Bio